Engineering Targeted Nanomedicines to Treat Disease
Programmable Medicine develops Hydroxyl Dendrimer Therapeutics (HDTs), a clinically validated nanomedicine platform that selectively targets activated inflammatory cells without a targeting ligand minimizing off-target toxicity to normal cells.
The HDT Platform Has Demonstrated Consistent Safety And Biological Activity Across Multiple Therapeutic Areas — In Humans, Not Just Models.
8 clinical trials
Rigorous testing across diverse disease indications.
100+ patients treated
Real-world clinical experience with a clean safety profile.
3 phase 2 studies
Advanced development stage across multiple programs.
Multiple platform companies
A scalable model generating target focused operating entities.
Hydroxyl Dendrimer Therapeutics (HDTs)
Hydroxyl Dendrimer Therapeutics (HDTs) are precisely engineered nanomedicines that selectively target activated inflammatory cells without the need for targeting ligands, reducing off-target toxicity to healthy tissues. By targeting the cells that drive disease progression, HDTs enable a more precise and effective approach to treating disease.
Building companies from science
One platform, many medicines. Individual therapeutic programs become focused operating companies — multiplying the impact of a single validated engine.
Validate on the platform
Form a Target focused company
Scale with partners
A Highly Reproducible Engine for Precision Medicines
The HDT platform is a highly reproducible engine for developing targeted nanomedicines. Rapidly scalable production, consistent pharmacology, and predictable safety enable one platform to support many medicines across multiple disease areas.
Rapid lead generation
Accelerated manufacturing to GMP
More rapid toxicology
Reproducible safety across products
From disease biology to clinical impact — a systematic path that translates cell-state understanding into therapeutic solutions.
Research Programs
Migaldendranib (MGB)
reduces IVT burden 5–9×
A targeted anti-angiogenic nanomedicine designed to treat retinal vascular diseases by selectively reaching activated cells that drive disease progression. Completed Phase 2a in diabetic macular edema and wet age-related macular degeneration demonstrating safety and efficacy with substantial reductions in intravitreal administration of anti-VEGF.
Acetylcysteine Zidrimer (ACZ)
diabetes inflammation
COVID Ph2; clean safety
A targeted anti-inflammatory therapy engineered to reduce harmful inflammation while minimizing systemic toxicity. Phase 2a clinical study in patients with hyperinflammatory state (COVID) resulted in doubling of survival and rapid normalization of systemic and brain inflammatory markers without drug-related adverse events.
18F-Flurimedrimer (FMD)
imaging
biomarker for I&I assets
A first-in-class imaging agent that selectively detects activated immune cells in regions of inflammation. Designed to visualize neuroinflammation and support diagnosis, patient selection, and treatment monitoring in diseases such as multiple sclerosis and Alzheimer's. Ongoing Phase 2a study has demonstrated specific uptake in brain lesions in MS patients.
Tamrada (64Cu/177Lu)
%201.avif)
A novel radiopharmaceutical theragnostic that combines precision imaging and targeted therapy in a single platform. Engineered to selectively target tumor-associated macrophages, offering a new approach to treating wide range of solid tumors while minimizing off-target exposure.
CSF1R Dendranib
myeloid cell-selective
An oral anti-inflammatory dendranib designed to selectively modulate activated immune cells, microglia and macrophages. Preclinical studies demonstrate the potential to reduce inflammation in obesity and neurological disorders.
JAK / Tyk2 / Inflammasome
Therapeutic Area Focused Companies
Each validated program becomes a focused operating company with its own team, capital and clinical strategy.
Ashvattha Therapeutics
Targeted anti-angiogenic therapy for retinal inflammatory disease, designed to reduce treatment burden for patients with neovascular eye disease.
Lead program Migaldendranib
Ironfist Therapeutics
Radiotherapeutic programs directing payloads to tumor-associated macrophages in the tumor microenvironment.
Lead program ⁶⁴Cu/¹⁷⁷Lu-Tamrada
Multiple ways to work with us
The platform creates value at every level — programs, companies and the engine itself. We structure partnerships to fit the science and the stage.
Strategic partnerships
Co-development of HDT programs in your therapeutic area, from discovery through clinical proof of concept.
Technology licensing
License the hydroxyl dendrimer platform for defined targets, payloads or fields of use.
NewCo development
Build a focused operating company around a validated program — with platform access and clinical data from day one.
Platform collaborations
Research collaborations applying cell-state targeting to new modalities, payloads and disease biology.
Investor opportunities
Participate at the platform level or in individual portfolio companies as they reach value inflection.
Transforming the treatment of disease through safe and effective targeted nanomedicines.
Our mission is to transform the treatment of diseases with safe and effective targeted nanomedicines referred to as HDTs (hydroxyl dendrimer therapeutics). HDTs treat inflammation-driven diseases with minimal off-target toxicity. Our clinically validated HDT platform has demonstrated human safety with effective targeting to activated immune cells in inflamed tissues.
Scientific Vision.
Proven Execution.
Programmable Medicine is led by a team with deep experience building companies, advancing innovative therapies, and creating long-term value.
Dr. Jeffrey Cleland brings more than 30 years of biotechnology leadership experience. As founding CEO of Versartis, he led one of biotech's most successful IPOs, helped raise over $500 million in capital, and currently serves as Co-Chair of Economic Growth and Innovation Committee at BIO.
Jay Zaveri is an entrepreneur, investor, and company builder. As Founder and Partner at Natural Capital and former Managing Partner at Social Capital, he helped oversee more than $1.1 billion in venture investments and founded CloudOn, later acquired by Dropbox.
30+ yrs
2 FDA Approvals
$1.6B+
$4.5B+
Partner with
Programmable Medicine
Join us in advancing precision nanomedicine and shaping the next generation of therapeutics.
